These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 31605106)
21. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615 [TBL] [Abstract][Full Text] [Related]
22. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer. Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252 [TBL] [Abstract][Full Text] [Related]
23. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247 [TBL] [Abstract][Full Text] [Related]
24. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment. Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696 [TBL] [Abstract][Full Text] [Related]
25. TRK inhibitors in TRK fusion-positive cancers. Drilon A Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426 [TBL] [Abstract][Full Text] [Related]
26. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651 [TBL] [Abstract][Full Text] [Related]
27. The promise of TRK inhibitors in pediatric cancers with NTRK fusions. Blauel ER; Laetsch TW Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663 [TBL] [Abstract][Full Text] [Related]
28. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion. Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937 [TBL] [Abstract][Full Text] [Related]
29. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294 [TBL] [Abstract][Full Text] [Related]
30. NTRK fusions in lung cancer: From biology to therapy. Harada G; Santini FC; Wilhelm C; Drilon A Lung Cancer; 2021 Nov; 161():108-113. PubMed ID: 34563714 [TBL] [Abstract][Full Text] [Related]
31. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]. Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737 [TBL] [Abstract][Full Text] [Related]
33. Tropomyosin receptor kinase inhibitors in the management of sarcomas. Wilding CP; Loong HH; Huang PH; Jones RL Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318 [TBL] [Abstract][Full Text] [Related]
34. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model. Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194 [TBL] [Abstract][Full Text] [Related]
35. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients. Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412 [TBL] [Abstract][Full Text] [Related]
36. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib. Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122 [TBL] [Abstract][Full Text] [Related]
37. Identifying patients with NTRK fusion cancer. Solomon JP; Benayed R; Hechtman JF; Ladanyi M Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934 [TBL] [Abstract][Full Text] [Related]
38. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk. Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Hong DS; Drilon A; Wirth LJ Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):1-20. PubMed ID: 38953725 [TBL] [Abstract][Full Text] [Related]
40. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Rolfo C; Drilon A; Hong D; McCoach C; Dowlati A; Lin JJ; Russo A; Schram AM; Liu SV; Nieva JJ; Nguyen T; Eshaghian S; Morse M; Gettinger S; Mobayed M; Goldberg S; Araujo-Mino E; Vidula N; Bardia A; Subramanian J; Sashital D; Stinchcombe T; Kiedrowski L; Price K; Gandara DR Br J Cancer; 2022 Feb; 126(3):514-520. PubMed ID: 34480094 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]